ksp-qrh-e3-irdye800
Peptideexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 22, 2018 (NCT03643068)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ksp-qrh-e3-irdye800
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04304781 | Phase 1 | Jun 30, 2020 | University of Michigan |
| NCT03852576 | Phase 1 | May 9, 2019 | University of Michigan |
| NCT03643068 | Phase 1 | Aug 22, 2018 | University of Michigan |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Michigan | Academic/Hospital | 3 | 3 | 1 | 2018 |
1 organizations
Page 1 / 1